Faecal contamination of lettuce heads after manure application

In recent years, an increasing number of disease outbreaks have been associated with consumption of contaminated vegetables. Thus, it has been speculated to what extent such contamination is associated with application of animal manure as fertilizer, which is particularly practiced in organic vegetable production where conventional fertilizers are prohibited. A field survey was therefore performed aiming to assess the survival and transfer of E. coli from animal manure to lettuces, with E. coli serving as an indicator of bacterial enteric pathogens. Animal manure was applied to 3 Danish fields prior to planting of lettuce seedlings, then 5-8 weeks later at the normal time of harvest, inner and outer leafs of 10 lettuce heads were pooled into one sample unit with a total of 50 pools per field. Additionally, in one field, 15 soil samples were collected weekly until the harvest time. E. coli was enumerated by plating 1 mL of 10-fold serial dilutions of 5 g of homogenized sample material, i.e. manure, soil and lettuce onto PetrifilmTM Select E. coli count plates (3M), which were then incubated 24 h at 44°C. The manure applied to the fields contained 3.0-4.5 Log10 E. coli CFU/g and E. coli was found in 36-54% of the pooled lettuce samples with a detection limit of 10 CFU/g. Numbers of E. coli in 14-20% of pooled lettuce samples exceeded a satisfactory microbiological hygiene criteria level of 100 CFU/g. The highest percentage of faecally contaminated lettuce heads (54%) coincided with the shortest growth period studied indicating that the time gap between application of manure and harvest and the survival of E. coli (and pathogens) influences the contamination of lettuce via manure amended soil. However, at the time of harvest, the numbers of E. coli in 5 of 15 soil samples were reduced below the detection limit and no samples exceeded 100 CFU/g. This is in contrast to the lettuce samples, where 20% of faecally contaminated samples had >100 E. coli/g, which may indicate that faeces contamination of crops could originate from alternative sources, such as contaminated water and wildlife. Comparisons of the genotype of isolated E. coli strains could help to elucidate this

Mine Action and Land Issues in Columbia

The purpose of this report is to examine the key links between land issues and mine action in Colombia and to provide practical ‘do no harm’ guidance to mine action organisations to ensure that mine action facilitates the return of Internally Displaced Persons (IDPs), promotes tenure security and contributes to longer term socio-economic recovery

An update on immune checkpoint therapy for the treatment of lynch syndrome

During the recent years, immune checkpoint-based therapy has proven highly effective in microsatellite instable (MSI) solid tumors irrespective of organ site. MSI tumors are associated with a defective mismatch repair (MMR) system and a highly immune-infiltrative tumor microenvironment—both characteristics of Lynch syndrome. Lynch syndrome is a multi-tumor syndrome that not only confers a high risk of colorectal and endometrial cancer but also cancer in, eg the upper urinary tract, ovaries, and small bowel. Since the genetic predisposition for Lynch syndrome are pathogenic variants in one of the four MMR genes, MLH1, MSH2, MSH6 or PMS2, most of the Lynch syndrome cancers show MMR deficiency, MSI, and activation of the immune response system. Hence, Lynch syndrome cancer patients may be optimal candidates for immune checkpoint-based therapies. However, molecular differences have been described between sporadic MSI tumors (developed due to MLH1 promoter hypermethylation) and Lynch syndrome tumors, which may result in different treatment responses. Furthermore, the response profile of the rare Lynch syndrome cases may be masked by the more frequent cases of sporadic MSI tumors in large clinical trials. With this review, we systematically collected response data on Lynch syndrome patients treated with FDA- and EMA-approved immune checkpoint-based drugs (pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab, and nivolumab) to elucidate the objective response rate and progression-free survival of cancer in Lynch syndrome patients. Herein, we report Lynch syndrome-related objective response rates between 46 and 71% for colorectal cancer and 14–100% for noncolorectal cancer in unselected cohorts as well as an overview of the Lynch syndrome case reports. To date, no difference in the response rates has been reported between Lynch syndrome and sporadic MSI cancer patients